drugset / Trial / NCT05008861
Gut Microbiota Reconstruction for NSCLC Immunotherapy
NaSingle-groupOpen-labelTreatment
Summary
In this study, patients with locally advanced or metastatic NSCLC after first-line treatment with PD-1/PDL-1 monoclonal antibody will be treated with Gut Microbiota reconstruction(such as FMT) combined with PD-1/PDL-1 monoclonal antibody. We will evaluate the safety of FMT in the treatment of advanced NSCLC, and analyze the effect of FMT on intestinal flora and immunophenotype of patients.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |